--- title: "Why Embecta Stock Plummeted Today" type: "News" locale: "en" url: "https://longbridge.com/en/news/285287738.md" description: "Embecta's stock plummeted 57.8% following a disappointing fiscal Q2 report, with adjusted earnings per share of $0.27 on sales of $221.8 million, missing analyst expectations of $0.42 per share and $235.7 million in sales. The company also reported a 14.4% year-over-year sales decline and lowered its full-year sales guidance to $1.015-$1.035 billion, raising concerns about its growth outlook. Additionally, adjusted operating margins are now expected to be between 22.25% and 23.25%, down from previous estimates of 29%-30%." datetime: "2026-05-06T00:45:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/285287738.md) - [en](https://longbridge.com/en/news/285287738.md) - [zh-HK](https://longbridge.com/zh-HK/news/285287738.md) --- # Why Embecta Stock Plummeted Today ## Key Points - Embecta's recent quarterly report arrived with disappointing results. - Sales and earnings for fiscal Q2 came in far weaker than anticipated. - Embecta's outlook appears weaker following its latest quarterly report. - These 10 stocks could mint the next wave of millionaires › **Embecta** (NASDAQ: EMBC) stock crashed Tuesday following the company's latest quarterly report. The medical-device specialist's share price ended the daily session down 57.8%. Before the market opened this morning, Embecta published results for the second quarter of its 2026 fiscal year -- which ended March 31. The company's sales and earnings for the period came in significantly weaker than expected, and investors aren't feeling optimistic about the near-term future. _**Will AI create the world's first trillionaire?** Our team just released a report on the one little-known company, called an "Indispensable Monopoly" providing the critical technology Nvidia and Intel both need. **Continue »**_ Image source: Getty Images. ## Embecta posted big misses in fiscal Q2 With its fiscal Q2 report, Embecta announced non-GAAP (adjusted) earnings per share of $0.27 on sales of $221.8 million. Meanwhile, the average analyst estimate had called for the business to record an adjusted profit of $0.42 per share on sales of roughly $235.7 million. Embecat's sales unexpectedly declined 14.4% year over year in fiscal Q2, and margins were significantly softer tahn anticipated. The company recorded an adjsuted earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of 29.1% in the quarter -- down from a margin of 37.5% in last year's quarter. ## What's on deck for Embecta? With its fiscal Q2 report, Embecta lowered its full-year sales guidance to between $1.015 billion and $1.035 -- down from previous guidance for sales between $1.071 billion and $1.093 billion. The downward sales revision doesn't look massive, but it does raise questions about the company's near-term growth outlook. Meanwhile, the company's adjusted operating margin is now expected to be between 22.25% and 23.25% -- representing a substantial reduction from the previous guidance for a margin between 29% and 30% in the period. The company expects to close its acquisition of Owen Mumford and for the purchase to have a dilutive impact on earnings of roughly $0.15 per share. While acquisition-related expenses will present an earnings headwind, the company's move to lower guidance on adjusted earnings per share from between $2.80 and $3 to between $1.55 per share and $1.75 per share raises some big questions for investors. ## Where to invest $1,000 right now When our analyst team has a stock tip, it can pay to listen. After all, _Stock Advisor’s_ total average return is 963%\* — a market-crushing outperformance compared to 201% for the S&P 500. They just revealed what they believe are the **10 best stocks** for investors to buy right now, **available when you join _Stock Advisor._** **See the stocks »** _\*Stock Advisor returns as of May 5, 2026._ _Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy._ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [EMBC.US](https://longbridge.com/en/quote/EMBC.US.md) - [IHI.US](https://longbridge.com/en/quote/IHI.US.md) - [XHE.US](https://longbridge.com/en/quote/XHE.US.md) - [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md) - [NVDA.US](https://longbridge.com/en/quote/NVDA.US.md) - [INTC.US](https://longbridge.com/en/quote/INTC.US.md) - [NVD.DE](https://longbridge.com/en/quote/NVD.DE.md) ## Related News & Research - [Lifeward Delays Quarterly Report Amid Deal Accounting](https://longbridge.com/en/news/286586728.md) - [Coherent Corp. Rocked by Major Insider Stock Move From Company Director](https://longbridge.com/en/news/286343834.md) - [OLD REPUBLIC DECLARES SECOND QUARTER REGULAR DIVIDEND OF 31.5 CENTS PER SHARE | ORI Stock News](https://longbridge.com/en/news/286552447.md) - [Edwards Lifesciences CVP, Strategy/Corp Development Sold Shares Worth Over $1.4M](https://longbridge.com/en/news/286822028.md) - [embecta Completes Acquisition of Owen Mumford Holdings Limited](https://longbridge.com/en/news/286571686.md)